Search Results
Your search for ,foR matches 32393 pages
Showing 20801 - 20850ASH 2016: New CAR T-Cell Therapy Holds Promise for Children and Young Adults With Hard-to-Treat ALL in Phase I Trial
Children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL) who receive chimeric antigen receptor (CAR) T-cell therapy targeting CD22, a protein found on the surface of leukemic cells, appear to mount a clinical response and, in some cases, achieve remission....
ASH 2016: Preventative Antibiotics Could Prevent Clostridium difficile Among Stem Cell Transplant Recipients
It may be possible to safely prevent one of the most common—and costly to treat—infections contracted by hospitalized patients undergoing bone marrow transplantation for the treatment of blood cancers, according to a study from the Abramson Cancer Center at the University of...
ASH 2016: New Chemotherapy Delivery Method Improves Survival After Bone Marrow Transplant in Older Patients With AML
A new analysis presented by Lancet et al at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 906) found older patients with acute myeloid leukemia (AML) survived longer after receiving an allogeneic stem cell transplant if they were first treated with the...
Assessment of Therapeutic Response by Intrinsic Subtype for HER2-Positive Breast Tumors
In an analysis of outcomes in the North Central Cancer Treatment Group/Alliance N9831 trial reported in the Journal of the National Cancer Institute, Perez et al found that patients with tumors scored as HER2-enriched or luminal subtype derived a recurrence-free survival benefit from the addition...
FDA Grants sBLA to Pembrolizumab for the Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–programmed cell death protein 1 (PD-1) therapy, for the treatment of patients with refractory classical Hodgkin lymphoma or for...
Psychotropic and Opioid Medication Use in Older Patients With Breast Cancer Across the Care Trajectory
A new McGill University study published by Syrowatka et al in JNCCN – Journal of the National Comprehensive Cancer Network found that most patients with breast cancer aged 65 and older use psychotropic and opioid medications during active treatment, often in the first year of...
Having a Child With Cancer May Adversely Affect Parents’ Income and Employment
Having a child with cancer led to income reductions for parents and job discontinuation among mothers in a recent study, even after adjusting for prediagnosis sociodemographic factors. Published by Norberg et al in Cancer, the findings indicate that childhood cancer affects parents' income and...
Increased Morbidity and Mortality in HCT Survivors vs Other Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Chow et al found that hematopoietic cell transplantation survivors had higher rates of morbidity and mortality compared with a matched population of patients with cancer not undergoing hematopoietic cell transplantation. The study involved...
High Frequency and Poor Outcome of Philadelphia Chromosome–Like ALL Reported in Adults
In a study reported in the Journal of Clinical Oncology, Roberts et al found a high frequency of Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) in adults with B-cell ALL and poorer outcome with conventional therapy in these patients. Frequency of Disease The frequency...
EORTC-NCI-AACR 2016: Liquid Biopsies Identify Molecular Alterations Driving GI Cancer Drug Resistance in Nearly 80% of Patients
Ryan Corcoran, MD, PhD, Translational Research Director of the Center for Gastrointestinal Cancers at Massachusetts General Hospital (MGH) Cancer Center, described to attendees of the 2016 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics the results of a program at MGH focused...
EORTC-NCI-AACR 2016: ‘Remarkable Antitumor Activity’ in Phase I Studies of PDGFRα and KIT Mutation Inhibitors
Two studies at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Munich, Germany focused on the inhibition of mutations in the KIT and PDGFRα oncogenes. These genes provide instructions for making proteins that are part of a family of proteins called receptor...
Outreach to Patients With Cirrhosis Doubles Early Screening Rates for Liver Cancer
Proactive outreach to cirrhosis patients in a safety net health system successfully doubled their screening rates for liver cancer, UT Southwestern Medical Center researchers found in a study published by Singal et al in Gastroenterology. Cirrhosis patients are at high risk to develop liver...
RSNA 2016: Large Study Finds No Evidence for Age-Based Mammography Cutoff
In the largest-ever study on screening mammography outcomes, researchers found that there is no clear cutoff age to stop breast cancer screening. The findings were presented November 28, 2016, at the 2016 Annual Meeting of the Radiological Society of North America (RSNA). This research adds support ...
Association of Extent of Surgeon-Assessed Resection on Outcome in High-Risk Neuroblastoma
In an analysis of patients with high-risk neuroblastoma from the Children’s Oncology Group A3973 study reported in the Journal of Clinical Oncology, von Allmen et al found that surgeon-assessed resection of at least 90% was associated with improved event-free survival and a reduced cumulative ...
Obesity/Overweight and Lower Activity Level May Increase Risk of Taxane-Induced Neuropathy in Women With Invasive Breast Cancer
Greenlee et al found that obesity, overweight, and low levels of moderate-to-vigorous physical activity were associated with an increased risk of taxane-related peripheral neuropathy in women with invasive breast cancer, according to a study reported in the Journal of the National Cancer Institute. ...
High-Dose Chemotherapy and Autologous PBSCT for Relapsed Metastatic Germ Cell Tumors
In a retrospective analysis reported in the Journal of Clinical Oncology, Adra et al found that good survival outcomes were achieved with the use of high-dose chemotherapy and peripheral blood stem cell transplantation (PBSCT) in second-, third-, or later-line treatment of patients with relapsed...
Alcohol Intake Associated With Modest Increase in Risk of Melanoma
Although alcohol consumption is associated with increasing the risk of many cancers, including liver, pancreatic, colon, rectal, and breast, the link between alcohol and higher risk of melanoma is equivocal. Now, a large prospective study by Rivera et al investigating the link between alcohol...
FDA Grants Full Approval and Label Update for Ponatinib in CML and ALL
The U.S. Food and Drug Administration (FDA) has granted ponatinib (Iclusig) full approval for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) for whom no ...
ASCO Releases Criteria for High-Quality Clinical Pathways in Oncology
ASCO today released Criteria for High-Quality Clinical Pathways in Oncology, a set of 15 inter-related criteria that provide an overarching framework for assessing pathway programs in the United States. ASCO developed the criteria to guide stakeholders in assessing the quality, utility, and...
FDA Grants Priority Review to Pembrolizumab for New Indication in Microsatellite Instability–High Cancer
On November 28, the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda) for the treatment of previously treated patients with advanced microsatellite instability–high (MSI-H) cancer. The FDA granted...
Projected Financial Burden of Targeted Therapies for Chronic Lymphocytic Leukemia
In an analysis reported in the Journal of Clinical Oncology, Chen et al predicted that an increase in the number of patients living with chronic lymphocytic leukemia (CLL) due to improved treatment with oral targeted therapies will be accompanied by a markedly increased overall cost to patients and ...
Can Mindfulness-Based Cognitive Therapy Reduce Distress in Patients With Advanced Prostate Cancer?
Chambers et al found that a mindfulness-based cognitive therapy intervention did not improve measures of distress or anxiety vs minimally enhanced usual care among men with advanced prostate cancer, according to an Australian study reported in the Journal of Clinical Oncology. In the study, 189...
Study Finds Serum DNA Methylation an Early Marker of Response and Survival in Metastatic Breast Cancer
In the Translational Breast Cancer Research Consortium (TBCRC) 005 prospective biomarker study, reported in the Journal of Clinical Oncology by Visvanathan et al, a cumulative methylation index was found to be predictive of progression-free survival, overall survival, and disease status at first...
NCCN Imaging Appropriate Use Criteria Published for 15 Additional Guidelines
The National Comprehensive Cancer Network® (NCCN®), a Centers for Medicare & Medicaid Services (CMS)-approved provider-led entity for imaging appropriate use criteria, continues to build its library of these standards and has published NCCN Imaging Appropriate Use Criteria™ for an ...
AMA Statement on Opening Day Court Case Against Anthem-Cigna Deal
Andrew W. Gurman, MD, President of the American Medical Association (AMA), issued the following statement on November 21: “The nation’s slide toward health insurance monopolies will be contested in federal court today as the U.S. Department of Justice (DOJ) and a bipartisan group of...
Study Shows Modestly Reduced Breast Cancer Recurrence Risk With Increased Protein Intake Independent of Tumor Insulin Receptor Status
In an analysis in the Nurses’ Health Study population reported in the Journal of Clinical Oncology, Holmes et al found modest reductions in the risk for distant recurrence of breast cancer with greater protein intake. No associations with intake of essential amino acids, branched-chain amino...
Link Between Previous Treatment for Depression and Increased Risk of Receiving Nonguideline Treatment in Early-Stage Breast Cancer
Women with early-stage breast cancer previously treated for depression were more likely to receive nonguideline treatment for breast cancer, “probably contributing to poorer overall and cancer-specific survival,” according to a nationwide Danish cohort study reported in the Journal of...
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From ASCT in NPM1-Mutant AML
In an analysis of a French trial reported in the Journal of Clinical Oncology, Balsat et al found that postinduction minimal residual disease was predictive of outcome and benefit from allogeneic stem cell transplantation (ASCT) in patients with NPM1-mutant acute myeloid leukemia (AML). The study...
Gleevec Is Saving My Life but at a Cost
Like many patients in the chronic phase of chronic myeloid leukemia (CML), my cancer was discovered during a routine physical, when an off-the-chart white blood cell count signaled a serious problem that my primary care physician attributed to unspecified internal bleeding. Fortunately for me, my...
Long-Term Effects of Finasteride in Patients From the Prostate Cancer Prevention Trial
In the Prostate Cancer Prevention Trial finasteride was found to reduce the risk of low-grade prostate cancer but to have no effect on overall survival. Results of the trial, in which 18,880 men were randomized to receive finasteride or placebo for 7 years, were reported in 2003. In a recent study...
Genetic Markers Associated With Pathologic Complete Response Identified in HER2-Positive Breast Cancer
In an analysis reported in JAMA Oncology, Fumagalli et al identified genetic markers associated with pathologic complete response among women with early-stage HER2-positive breast cancer receiving neoadjuvant therapy in the phase III NeoALTTO trial. Christos Sotiriou, MD, PhD, of Institut Jules...
Primary Care Physician Involvement in Decision-Making in Breast Cancer
Most women with breast cancer reported high primary care physician quality, engagement, and communication, with a minority reporting high levels of primary care physician participation in treatment decisions, according to a study reported by Lauren P. Wallner, PhD, MPH, of the University of...
SU2C Launches $7.5 Million Initiative in Research Grants Focusing on Immuno-oncology
Stand Up To Cancer (SU2C) is making $7.5 million in research grants available to early-career scientists who are pursuing innovative cancer research projects focusing on immuno-oncology, the American Association for Cancer Research recently announced. Funded by a grant from SU2C Visionary...
Adrian Lee, PhD, Named Director of the Institute for Precision Medicine at Pitt
Breast cancer researcher Adrian Lee, PhD, has been named Director of the Institute for Precision Medicine (IPM), a joint effort by the University of Pittsburgh Medical Center (UPMC) and the University of Pittsburgh to move biomedical research into personalized well-being and clinical care. Dr....
FDA Approves Nivolumab for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
On November 10, 2016, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. Approval was based on data from an...
Advanced Practitioners Convene at Fourth Annual JADPRO Live at APSHO
Launched in 2012 by Harborside Press, publisher of the Journal of the Advanced Practitioner in Oncology (JADPRO) and The ASCO Post, this year’s JADPRO Live at APSHO conference topped previous attendance records with nearly 1,100 attendees. APSHO, the Advanced Practitioner Society in Hematology and...
American Society of Hematology Honors David Grimwade, PhD, Posthumously With the 2016 Exemplary Service Award
The American Society of Hematology (ASH) will recognize the late David Grimwade, PhD, formerly of King’s College London and Guy’s and St. Thomas’ NHS Foundation Trust with the 2016 Exemplary Service Award for his exceptional years of service and dedication to the Society’s global programs that...
ASH Honors J. Evan Sadler, MD, PhD, and Ayalew Tefferi, MD, With the 2016 Henry M. Stratton Medal
The American Society of Hematology (ASH) will recognize J. Evan Sadler, MD, PhD, of Washington University School of Medicine in St. Louis, and Ayalew Tefferi, MD, of Mayo Clinic College of Medicine, with the 2016 Henry M. Stratton Medal for their seminal contributions in the areas of basic and...
ASH Reports Highest-Scoring Abstracts by Early-Career Researchers for Annual Meeting
The American Society of Hematology (ASH) recently announced that the following trainees received the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow for the 58th ASH Annual Meeting, December...
Drainage of Massive Ascites: Patient of Nicholas Senn, MD
Prior to the 20th century, there were very few specific therapies for disease. Many diseases, especially cancers and infections, resulted in accumulations of fluid or pus in body cavities. Physicians had to become masters of the trocar, needle, and catheter. They learned to artfully remove fluid...
Expect and Encourage Questions About Breast Reconstruction
An article in The New York Times about women who had chosen not to have reconstruction following breast cancer surgery might prompt questions from newly diagnosed patients considering their options.1 Deanna J. Attai, MD, FACS, told The ASCO Post that whenever an article on breast cancer appears in...
Helping Patients With Breast Cancer Decide Whether to Have Reconstruction
A “nascent movement to ‘go flat’” is how an article in The New York Times characterized the decisions by some women to opt out of reconstruction following surgery for breast cancer.1 The article examined the reasons several patients made that decision, which included avoiding multiple surgeries and ...
Elisabeth Heath, MD, FACP, Honored With 2016 Michigan Cancer Consortium Champion Award
Elisabeth Heath, MD, FACP, Leader of the Genitourinary Oncology Multidisciplinary Team and the Patricia C. and E. Jan Hartmann Endowed Chair for Prostate Cancer Research at the Barbara Ann Karmanos Cancer Institute, was recently honored with the Michigan Cancer Consortium’s inaugural Champion...
Dave, Dave, Dave
It was 1983, and I was in my third year as an attending physician at a major East Coast university medical center and just 5 years out of fellowship. As was common at the time, I saw and treated all malignancies except leukemia and gynecologic cancers. In the middle of a typically busy day at the ...
FDA Approves Daratumumab in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Multiple Myeloma
On November 21, 2016, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone, or bortezomib (Velcade) and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior...
Center for Leukemia and Lymphoma Research at UNMC Renamed Dr. James O. Armitage Center for Leukemia and Lymphoma Research
The University of Nebraska Board of Regents voted to rename an area of the University of Nebraska Medical Center (UNMC) in honor of a longtime professor who has made extraordinary contributions to the institution. The Center for Leukemia and Lymphoma Research, established in 2003, was renamed by...
Safety Profile of Nivolumab Monotherapy in Advanced Melanoma
As reported in the Journal of Clinical Oncology, Weber et al performed a pooled analysis of the safety profile of nivolumab (Opdivo) monotherapy in advanced melanoma, including a focus on potential immune-related (select) adverse events. The analysis pooled safety data from 576 patients receiving...
Pooled Analysis of Outcome With Nivolumab Alone or With Ipilimumab in Advanced Mucosal or Cutaneous Melanoma
A pooled analysis of outcomes in patients receiving nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) for advanced mucosal or cutaneous melanoma in clinical trials was reported by D’Angelo et al in the Journal of Clinical Oncology. The pooled analysis involved 889 patients who...
CAP/ASCP/ASCO Guideline on HER2 Testing and Clinical Decision-Making in Gastroesophageal Adenocarcinoma
As reported by Angela N. Bartley, MD, of St Joseph Mercy Hospital, Ann Arbor, and colleagues in the Journal of Clinical Oncology, the College of American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), and ASCO have released a guideline on HER2 testing and clinical...
Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions
Memorial Sloan Kettering Cancer Center, Rockefeller University, and Weill Cornell Medicine have announced that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd and health-care investment firms Bay City Capital ...
